

Terminal Complement Complex antibody [aE11]

Cat. No. GTX54459

Host	Mouse
Clonality	Monoclonal
Isotype	IgG2a
Applications	IHC-P, IHC-Fr, FCM, ELISA, Neutralizing /Inhibition
Reactivity	Human, Pig, Horse

Package

50 µg

Applications

Application Note

*Optimal dilutions/concentrations should be determined by the researcher.

Suggested dilution	Recommended dilution
IHC-P	Assay dependent
IHC-Fr	Assay dependent
FCM	Assay dependent
ELISA	Assay dependent
Neutralizing /Inhibition	Assay dependent

Note : Cryosections of 10 µm were dried, fixed in acetone at 4°C for 10 min, dried and blocked for 20 min with PBSA. Antibody aE11 inhibits platelet activation by antiphospholipid antibody serum.

Not tested in other applications.

Product Note

Monoclonal antibody aE11 reacts with a C9 neoantigen of the terminal complement complex (TCC) consisting of C5B, C6, C7, C8, C9 (PubMed ID: 4035298). The TCC contains neoantigens that are absent from the individual native components.- C9 neoantigens are present both in the membrane-bound (MAC) and the fluid-phase (SC5b-9) complex.

Properties

Form	Liquid
Buffer	Filter-sterilized PBS, 0.1% BSA
Preservative	No preservatives
Storage	Store as concentrated solution. Centrifuge briefly prior to opening vial. Store at 4°C.
Concentration	100 µg/ml (Please refer to the vial label for the specific concentration.)
Purification	Protein G purified
Endotoxin	< 24 EU/mg (Determined by LAL assay)
Conjugation	Unconjugated



For full product information, images and publications, please visit our [website](#).

For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.

Note

Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.



For full product information, images and publications, please visit our [website](#).